Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences, has entered into a strategic global licensing agreement with Brazil-based Braile Biomedica to commercialise its cutting-edge Transcatheter Aortic Valve Implantation (TAVI) technology across India, Europe, and other select markets.
This move marks Zydus Medtech’s formal entry into the high-growth interventional cardiology space, where TAVI is fast emerging as a minimally invasive alternative to open-heart surgery for aortic valve replacement. The global TAVI market is valued at over USD 6 billion and continues to expand due to rising cases of aortic stenosis and increasing preference for non-invasive cardiac procedures.
Under the pact, Zydus MedTech will hold exclusive rights to commercialise Braile’s balloon-expandable TAVI system, leveraging its regulatory and market expertise. Braile Biomedica, a pioneer in cardiovascular devices, will manufacture the valve system, while Zydus retains rights to produce certain components — ensuring operational flexibility and localised innovation.
What sets this TAVI system apart is its origin in the doctoral research of Dr. Domingo Braile, one of Brazil’s leading cardiac surgeons. The valve uses a unique bovine pericardium sheet in a single-piece design, promising improved biocompatibility, longevity, and performance. The solution is engineered for real-time deployment, navigating complex vascular anatomies with precision — a hallmark of next-gen cardiac innovation.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, stated, “This partnership brings together Zydus’ commercial strengths and Braile’s technological excellence to redefine structural heart care for high-risk patients globally.”
Patricia Braile, CEO of Braile Biomedica, added, “Collaborating with Zydus allows our life-saving TAVI innovation to reach new continents and positively impact patients worldwide.”
The two companies also plan to jointly launch further cardiovascular innovations over the next three years, backed by a clinical research program commencing in 2026.
This collaboration further affirms Zydus Lifesciences’ commitment to transforming lives through breakthrough healthcare technologies.
